Delving into the Latest Updates on GSK-3862995B with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

GSK-3862995, GSK3862995, GSK3862995B

Target

IL-33

Action

inhibitors

Mechanism

IL-33 inhibitors(Interleukin-33 inhibitors)

Therapeutic Areas

Respiratory Diseases

Active Indication

Pulmonary Disease, Chronic Obstructive

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

GSK PlcGlaxoSmithKline Research & Development Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This study aims to assess the ethnic sensitivity of GSK3862995B in terms of safety, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) in healthy participants of Chinese, Japanese, and European ancestry to enable the inclusion of Chinese and Japanese participants in future global studies.

Start Date20 May 2025

Sponsor / Collaborator

GSK Plc

NCT06154837

/ RecruitingPhase 1

A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease

The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).

Start Date27 Nov 2023

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with GSK-3862995B

Login to view more data

100 Translational Medicine associated with GSK-3862995B

Login to view more data

100 Patents (Medical) associated with GSK-3862995B

Login to view more data

100 Deals associated with GSK-3862995B

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 1	United States	GSK Plc	27 Nov 2023
Pulmonary Disease, Chronic Obstructive	Phase 1	Germany	GSK Plc	27 Nov 2023
Pulmonary Disease, Chronic Obstructive	Phase 1	United Kingdom	GSK Plc	27 Nov 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data